ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC) OPTIONS

These side effects were notably milder in comparison to an inhibitor of both equally bromodomains. An in depth molecular Examination also revealed that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes.  ― Stephen Taylor- "Our study disclosed the crucial role of the KLF16/MYC regulatory axis in modulating